Proposing Bromo-Epi-Androsterone (BEA) for Post-Traumatic Stress Disorder (PTSD)
Cells · 21.07.2025 · 14 (14) · 1120
DOI: 10.3390/cells14141120 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cells, online erschienen am 21.07.2025. Verfasst von Coad Thomas Dow und 1 weiteren Autor:innen. Beteiligte Einrichtung: McPherson Eye Research Institute, University of Wisconsin-Madison, Madison, WI 53705, USA. Hauptthemen laut MEDLINE: Stress Disorders, Post-Traumatic, Dehydroepiandrosterone. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 98 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Protibea Therapeutics, Inc..
Abstract (Originalsprache)
Post-traumatic stress disorder (PTSD) has traditionally been viewed as a psychiatric disorder of fear, memory, and emotional regulation. However, growing evidence implicates systemic and neuroinflammation as key contributors. Individuals with PTSD often exhibit elevated blood levels of pro-inflammatory cytokines such as IL-1β, IL-6, TNF-α, and C-reactive protein, indicating immune dysregulation. Dysfunctions in the hypothalamic–pituitary–adrenal (HPA) axis marked by reduced cortisol levels impair the body’s ability to regulate inflammation, allowing persistent immune activation. Circulating cytokines cross a weakened blood–brain barrier and activate microglia, which release additional inflammatory mediators. This neuroinflammatory loop can damage brain circuits critical to emotion processing including the hippocampus, amygdala, and prefrontal cortex, and disrupt neurotransmitter systems like serotonin and glutamate, potentially explaining PTSD symptoms such as hyperarousal and persistent fear memories. Rodent models of PTSD show similar inflammatory profiles, reinforcing the role of neuroinflammation in disease pathology. Bromo-epi-androsterone (BEA), a synthetic analog of dehydroepiandrosterone (DHEA), has shown potent anti-inflammatory effects in clinical trials, significantly reducing IL-1β, IL-6, and TNF-α. By modulating immune activity, BEA represents a promising candidate for mitigating neuroinflammation and its downstream effects in PTSD. These findings support the rationale for initiating clinical trials of BEA as a novel therapeutic intervention for PTSD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- McPherson Eye Research Institute, University of Wisconsin-Madison, Madison, WI 53705, USA.
- Keck School of Medicine, University of Southern California, Los Angeles, CA 90089, USA.
ORCID-Profile: Coad Thomas Dow
Förderung
- Protibea Therapeutics, Inc.
Zitieren
APA
Dow, C. T., & Obaid, L. (2025). Proposing Bromo-Epi-Androsterone (BEA) for Post-Traumatic Stress Disorder (PTSD). Cells, 14(14), 1120. https://doi.org/10.3390/cells14141120
Vancouver
Dow CT, Obaid L. Proposing Bromo-Epi-Androsterone (BEA) for Post-Traumatic Stress Disorder (PTSD). Cells. 2025;14(14):1120. doi:10.3390/cells14141120
BibTeX
@article{Dow2025,
author = {Dow, Coad Thomas and Obaid, Liam},
title = {Proposing Bromo-Epi-Androsterone (BEA) for Post-Traumatic Stress Disorder (PTSD)},
journal = {Cells},
year = {2025},
volume = {14},
number = {14},
pages = {1120},
doi = {10.3390/cells14141120}
}
EUVIMED